The drug called omalizumab, marketed as Xolair, is given as a monthly injection by a doctor and has been shown to reduce the number of times a child has a severe attack. ❋ Unknown (2010)
A new drug called "omalizumab" (sounds like something Aleister Crowley would utter while trying to breathe life into a homunculus) promises to stop allergic reactions by blocking the action of the antibodies that trigger the reaction. ❋ Unknown (2001)
In the study, 11 children with milk allergies were given omalizumab for nine weeks before being given a dose of two grams of milk protein, Nadeau said. ❋ Unknown (2011)
Researchers at Stanford University and Children's Hospital Boston created a new, expedited approach in which children were exposed to small amounts of milk powder along with the allergy drug omalizumab. ❋ Unknown (2011)
Last month the Scottish Medicines Consortium (SMC) accepted the use of omalizumab for children in Scotland aged 6 to 11 years with severe, persistent allergic asthma who are prescribed chronic systemic steroids [6]. ❋ Unknown (2010)
(NICE) has decided against recommending omalizumab for children aged 6 to 11 years with severe, persistent allergic asthma in England and Wales because it does not consider it to be ❋ Unknown (2010)
By targeting IgE, omalizumab can prevent the onset of debilitating symptoms, such as shortness of breath and wheezing, in severely affected patients. ❋ Unknown (2010)
It is estimated that just over 300 of these children may be eligible for treatment with omalizumab [10]. ❋ Unknown (2010)
More recently omalizumab was approved by the same regulator as add-on therapy for severe persistent allergic asthma in children aged 6 to 11 years [3]. ❋ Unknown (2010)
Results from a pivotal study submitted to NICE showed that omalizumab reduced asthma attacks by a third after 24 weeks of treatment [2] and provided an overall reduction of 50% at one year [2]. ❋ Unknown (2010)
In light of this, Nice does intend to review its guidance on omalizumab for both age groups at the earliest opportunity. ❋ Unknown (2010)
We understand that this may be a disappointing decision, especially as Nice does recommend omalizumab for some people aged twelve and over. ❋ Unknown (2010)
THURS.AY, July 16 (HealthDay News) -- The U.S. Food and Drug Administration has begun a safety review of the asthma drug Xolair (omalizumab) after reports of an increased risk of heart attack, abnormal heart rhythm, heart failure and stroke, the agency said Thursday.
XOLAIR (omalizumab) is an injected drug for asthma related allergies. ❋ Unknown (2009)
Dr Tim Cave, Medical Director, Novartis UK said: "We are disappointed by NICE's initial decision and concerned that the small number of young children with severe asthma in whom omalizumab would be used will be denied access to this drug. ❋ Unknown (2010)
